Edwards Lifesciences (EW) Cash from Financing Activities (2009 - 2026)

Edwards Lifesciences' Cash from Financing Activities history runs 18 years deep, the most recent figure standing at -$451.2 million for Q1 2026.

• On a quarterly basis, Cash from Financing Activities fell 74.88% year-over-year to -$451.2 million in Q1 2026; TTM through Mar 2026 was -$1.2 billion, a 11.72% increase from a year earlier, with the FY2025 full-year figure at -$956.8 million, up 2.67% from the prior year.
• Cash from Financing Activities retreated to -$451.2 million in Q1 2026 per EW's latest filing, from -$11.4 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $61.7 million in Q1 2024 and bottomed at -$976.7 million in Q3 2024.
• The 5-year median for Cash from Financing Activities is -$206.6 million (2023), against an average of -$275.7 million.
• Across the five-year window, Cash from Financing Activities plunged 1252.26% in 2022 and surged 154.55% in 2025, its largest moves.
• Year by year, Cash from Financing Activities stood at -$838.4 million in 2022, then soared by 50.72% to -$413.2 million in 2023, then surged by 106.92% to $28.6 million in 2024, then plunged by 139.86% to -$11.4 million in 2025, then slumped by 3857.89% to -$451.2 million in 2026.
• Per Business Quant, the three latest EW Cash from Financing Activities figures stand at -$451.2 million (Q1 2026), -$11.4 million (Q4 2025), and -$740.1 million (Q3 2025).